Skip to main content

Table 1 The basic characteristics of the inclusion studies

From: ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

First Author Year Country Tumor stage Regimen of chemotherapy Genotyping method Nunber of cases Resistant Responder P (HWE) NOS score
CC CT TT CC CT TT
Kang 2006 Korean I-IV platinum-based chemotherapy Snapshot 60 15 5 0 20 16 4 0.763 8
Smith 2007 USA I-IV platium ± paditaxel chemotherapy PCR–RFLP 176 11 22 15 23 60 45 0.701 8
Steffensen 2008 Danish II-IV carboplatin and cyclophosphamide combined-chemotherapy TaqMan assay-based Real time PCR 100 3 7 2 12 34 42 0.239 8
Steffensen 2011 Danish I-IV Combined with carboplatin and paclitaxel PCR–RFLP 157 2 4 7 15 71 58 0.321 8
Bösmüller 2011 Germany I-III Standard carboplatin-taxane PCR–RFLP 41 6 5 3 7 9 11 0.098 8
Moxley 2013 USA IIIB-IV Platium- Based Chemotherapy PCR–RFLP 64 10 13 9 14 8 10 0.005 8
Qi BL 2013 China I-IV Platinum-based combination Snapshot 220 38 26 9 78 67 2 0.003 7
Huo XY 2017 China I-IV TP (paclitaxel / docetaxel + cisplatin / carboplatin / oxaliplatin) PCR–RFLP 280 43 29 16 104 82 6 0.049 7
Yang SY 2017 China III-IV Cisplatin / carboplatin, combined with cyclophosphamide / paclitaxel PCR–RFLP 209 28 31 12 70 67 1 0.000 7
Bao Y 2020 China II-IV cisplatin based Chemotherapy PCR–RFLP 559 209 124 47 115 55 9 0.473 8
  1. NOS Newcastle–Ottawa Scale, PCR–RFLP Polymerase chain reaction-restriction fragment length polymorphism, HWE Hardy–Weinberg equilibrium